LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

Search

Danaher Corp

Slēgts

SektorsVeselības aprūpe

188.74 5.35

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

178.99

Max

189.4

Galvenie mērījumi

By Trading Economics

Ienākumi

-168M

1B

Pārdošana

-887M

6B

P/E

Sektora vidējais

34.466

50.958

EPS

2.06

Dividenžu ienesīgums

0.77

Peļņas marža

17.291

Darbinieki

58,000

EBITDA

-560M

1.5B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+28.4% upside

Dividendes

By Acuity

Dividenžu ienesīgums

Sektora vidējais

0.77%

2.41%

Nākamie ieņēmumi

2026. g. 21. jūl.

Nākamais dividenžu datums

2026. g. 31. jūl.

Nākamais Ex dividenžu datums

2026. g. 26. jūn.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-12B

126B

Iepriekšējā atvēršanas cena

183.39

Iepriekšējā slēgšanas cena

188.74

Ziņu noskaņojums

By Acuity

23%

77%

57 / 342 Rangs Healthcare

Danaher Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Par Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
help-icon Live chat